摘要
目的：探讨使用恩替卡韦辅助治疗慢性乙型肝炎的近期疗效。方法以我院2013－04～2014－04间收治的慢性乙型肝炎患者140例为研究对象，将其随机分为观察组与对照组。对照组口服阿德福韦酯，观察组在此基础上增加服用恩替卡韦，比较两组患者临床效果。结果观察组患者在治疗后6周、治疗后12周及治疗后24周时，乙肝病毒脱氧核糖核酸（ HBV DNA）载量显著低于对照组（P＜0．05）。而转化生长因子β1（TGF－β1）水平的比较中，则未见显著差异（P＞0．05）。结论恩替卡韦可以作为一种辅助用药，有效作用于慢性乙型肝炎患者抗病毒治疗。
Objective To study the clinical effects of 24 weeks entecavir antiviral therapy on chronic hepatitis B.Methods A total of 140 patients, received from April 2013 to April 2014, with chronic hepatitis B were included in this study and randomly divided into study group and control group.Patients in control group were treated by adefovir dipivoxil and patients in study group were treated by entecavir ad-ditionally.The clinical effects were compared between two groups.Results The HBV DNA load in study group was significantly lower than that in control group, at 6 weeks, 12 weeks and 24 weeks after treatment.There was no significant difference of serum TGF-β1 between two groups（P〉0.05）.Conclusion Entecavir is a effective adjuvant drug in chronic hepatitis B antiviral therapy.
出处
《黑龙江医学》
2015年第5期520-522,共3页
Heilongjiang Medical Journal
基金
广东省科技计划项目(2005B360D1032)
